HC Wainwright Weighs in on Nuvation Bio Inc.'s Q2 2025 Earnings (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Nuvation Bio in a research note issued to investors on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the company will earn ($0.10) per share for the quarter. HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Nuvation Bio's Q3 2025 earnings at ($0.11) EPS.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its earnings results on Thursday, February 29th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04.

A number of other research analysts also recently commented on NUVB. Royal Bank of Canada increased their price target on shares of Nuvation Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, April 17th. Wedbush reiterated an "outperform" rating and issued a $5.00 target price on shares of Nuvation Bio in a report on Wednesday, May 15th. Jefferies Financial Group upgraded Nuvation Bio from a "hold" rating to a "buy" rating and increased their price target for the company from $1.40 to $10.00 in a report on Wednesday, March 27th. Finally, BTIG Research upgraded Nuvation Bio from a "neutral" rating to a "buy" rating and set a $5.00 price target for the company in a research report on Tuesday, March 26th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nuvation Bio has an average rating of "Buy" and an average target price of $6.60.

Nuvation Bio Stock Performance

NUVB stock traded down $0.20 during trading on Thursday, hitting $3.08. 968,642 shares of the company's stock traded hands, compared to its average volume of 1,195,943. The business has a fifty day simple moving average of $3.00 and a 200 day simple moving average of $2.09. Nuvation Bio has a 52 week low of $0.95 and a 52 week high of $4.16. The stock has a market capitalization of $671.59 million, a price-to-earnings ratio of -9.84 and a beta of 1.42.

Institutional Investors Weigh In On Nuvation Bio

Several hedge funds and other institutional investors have recently modified their holdings of the business. Beacon Pointe Advisors LLC bought a new stake in shares of Nuvation Bio during the fourth quarter valued at approximately $33,000. Susquehanna Fundamental Investments LLC purchased a new position in Nuvation Bio during the 1st quarter worth $79,000. Pinnacle Wealth Planning Services Inc. bought a new stake in Nuvation Bio during the 1st quarter valued at $105,000. Gladius Capital Management LP lifted its holdings in shares of Nuvation Bio by 92.6% in the 4th quarter. Gladius Capital Management LP now owns 30,967 shares of the company's stock worth $47,000 after buying an additional 14,885 shares during the period. Finally, TD Asset Management Inc grew its position in shares of Nuvation Bio by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 105,600 shares of the company's stock worth $142,000 after buying an additional 52,800 shares in the last quarter. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.